Embryo Genetic Analysis
Before an embryo is transferred, genetic testing can identify the healthiest candidates — reducing miscarriage risk, improving implantation rates, and offering peace of mind about inherited conditions.
From your first consultation through every monitoring visit and embryo transfer, the same physicians, nurses, and embryologists stay with you. Connected care means nothing about your treatment gets lost in translation.
Meet our teamPreimplantation Genetic Testing (PGT) is a laboratory procedure performed on embryos created through IVF before transfer to the uterus. A small number of cells are biopsied from the blastocyst and sent to a genetics laboratory for analysis.
Testing provides information about the sampled cells for your team to interpret alongside other assessments. It cannot screen for every condition, predict every embryo outcome, or guarantee a healthy pregnancy.
Tests embryos for the correct number of chromosomes (46 total). Results describe sampled cells, not every cell in an embryo. The test can produce mosaic or inconclusive findings and does not guarantee pregnancy or live birth.
Best for: Advanced maternal age, recurrent pregnancy loss, repeated IVF failure
Screens embryos for specific single-gene disorders — such as cystic fibrosis, sickle cell disease, BRCA mutations, Huntington's disease, and hundreds of others — when one or both parents are known carriers.
Best for: Known carriers of a specific inherited condition
Identifies chromosomal structural changes (translocations, inversions) that can cause IVF failure or recurrent miscarriage, even when one parent is a balanced carrier with no apparent health impact.
Best for: Couples with a known chromosomal structural rearrangement
Science that gives you confidence before transfer.
PGT significantly reduces the risk of specific chromosomal or genetic conditions — but it cannot screen for all possible abnormalities. It is an important risk-reduction tool, not an absolute guarantee. Your physician will discuss realistic expectations.
At the blastocyst stage (day 5–6), an embryologist uses a laser to remove a small number of trophectoderm cells (which become the placenta, not the baby). The embryo is then frozen while biopsy results are awaited. Biopsy can damage an embryo. Ask your team about this risk, result accuracy, and the possibility of having fewer embryos available for transfer.
Turnaround time depends on the test and laboratory. Ask your coordinator for the expected timeline and transfer schedule. Your physician will interpret the results with you.
PGT-A does not improve the chance of having a baby for everyone. HFEA reports no evidence from randomized trials of benefit for most IVF patients. It may reduce miscarriage in some circumstances, but may reduce embryos available for transfer. Discuss the evidence, risks, and costs for your situation.
Review abnormal, mosaic, or inconclusive findings with your physician and a genetic counselor before making decisions about embryo transfer or disposition. Results have limitations and must be interpreted in context.
PGT is a powerful tool for the right patients. Our physicians will help you determine whether it makes sense for your situation.